ABL Diagnostics Becomes ABL Texcell Diagnostics
https://www.businesswire.com/news/home/20260917377394/en/ABL-Diagnostics-Becomes-ABL-Texcell-Diagnostics
ABL Diagnostics Becomes ABL Texcell Diagnostics Read More »
ABL Diagnostics Announces UltraGene Respiratory Pathogens 21 After CE-IVD Registration by ABL SA Luxembourg
https://www.einpresswire.com/article/929034320/abl-diagnostics-announces-ultragene-respiratory-pathogens-21-after-ce-ivd-registration-by-abl-sa-luxembourg
ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations
https://www.einpresswire.com/article/928571332/abl-diagnostics-selected-by-the-vry-commercial-court-to-acquire-texcell-s-operations
ABL Diagnostics Selected by the Évry Commercial Court to Acquire TEXCELL’s Operations Read More »
DeepChek® & HybridChek TB Assays & SoftwareComplete Coverage for Tuberculosis Drug Resistance Testing by Amplicon & Hybrid Capture NGS Sequencing.
https://mailchi.mp/abldiagnostics/tb2026?e=e8da2024cf
ABL Diagnostics Confirms BSI Partnership for IVDR Transition and Long-Term Availability of its CE-IVD Medical Devices
https://www.einpresswire.com/article/927085611/abl-diagnostics-confirms-bsi-partnership-for-ivdr-transition-and-long-term-availability-of-its-ce-ivd-medical-devices
ABL Diagnostics Announces Renewal of U.S. Patent (US 8,859,198 B2) for Hepatitis B Genotyping and Antiviral Resistance
https://www.einpresswire.com/article/919178783/abl-diagnostics-announces-renewal-of-u-s-patent-us-8-859-198-b2-for-hepatitis-b-genotyping-and-antiviral-resistance
ABL Diagnostics Showcases Scientific Progress at EMHH 2026, Supporting Strategic Positioning in Molecular Technologies
https://www.einpresswire.com/article/918127065/abl-diagnostics-showcases-scientific-progress-at-emhh-2026-supporting-strategic-positioning-in-molecular-technologies
ABL Diagnostics Advances Platform-Agnostic NGS Strategy Through DeepChek® Verification on Element Biosciences’ AVITI™
https://www.einpresswire.com/article/918135269/abl-diagnostics-advances-platform-agnostic-ngs-strategy-through-deepchek-verification-on-element-biosciences-aviti
ABL Diagnostics Deepens Laboratory Footprint with Launch of HybridChek for HIV and Tuberculosis Whole Genome Sequencing
https://www.einpresswire.com/article/917550254/abl-diagnostics-deepens-laboratory-footprint-with-launch-of-hybridchek-for-hiv-and-tuberculosis-whole-genome-sequencing
ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026 (EN)
https://www.businesswire.com/news/home/20260601791272/en/ABL-Diagnostics-Presents-Its-Financial-Roadmap-and-Growth-Outlook-for-2026
ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026 (EN) Read More »